25 results about "Interstitial cystitis" patented technology

Provided is a Hunner-type interstitial cystitis therapeutic agent that can selectively inhibit IFN-γ without risk of biological contamination and can be stored at room temperature. Provided is a Hunner-type interstitial cystitis therapeutic agent or a reagent for test and research, comprising as an active ingredient a DNA oligonucleotide having a nucleotide sequence set forth in any of SEQ ID NO:1 to 3 and selectively binding to IFN-γ. A base, X, in the sequence of the DNA oligonucleotide having the nucleotide sequence set forth in SEQ ID NO: 3 is an artificially produced base, and the artificially produced base may be chemically modified with a low-molecular-weight compound, a medium-molecular-weight compound, a high-molecular-weight compound, a biopolymer, or a biocompatible polymer.

The invention provides systems and methods for providing a diagnostic examination to a patient, including, but not limited to a determination of the permeability of a patients' body cavity.

The invention provides a method of treating interstitial cystitis that applies therapeutic exomes to the bladder of a patient through intravesical administration. Unlike the intravesical administration of stem cells, the intravesical administration of exosomes permits a therapeutic amount of paracrine-active growth factors and cytokines to be applied to bladder tissue before they can voided by urination.

Provided is a therapeutic or prophylactic agent for pain or interstitial cystitis comprising N-[2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1H-indol-6-yl]-N-methyl-(2S)-2-(morpholin-4-yl) propanamide or a pharmaceutically acceptable salt thereof.

A method for treating a condition in a body where a biofilm on or proximate a tissue causes pain, irritation, and / or inflammation. One condition may be interstitial cystitis. The method for treating interstitial cystitis includes providing a catheter with a lumen and an elongate rod disposed within the lumen and routing the lumen through a urethra such that a distal end of the elongate rod is disposed in an interior of a bladder. Then connecting the elongate rod to a controller adapted to generate current and supplying a current at a first amperage from the controller to the distal end of the elongate rod. Applying the current for a predetermined time so as to disrupt a biofilm on or proximate to an interior wall of the bladder. A method for treating prostatitis is also disclosed.

The present invention relates to a composition for the prophylactic and / or therapeutic treatment of bladder infections (cystitis), kidney infections (pyelonephritis), bacterial vaginal infections (vaginosis), hematuria, interstitial cystitis, restless leg syndrome, premenstrual syndrome (PMS), loss of libido, anal eczema, hemorrhoids and / or urethritis as well as dermatitis, herpes, skin diseases and / or skin irritations.

A method for treating interstitial cystitis of a patient is disclosed. The method includes providing a catheter with a lumen and an elongate rod disposed within the lumen and routing the lumen through a urethra such that a distal end of the elongate rod is disposed in an interior of a bladder. Then connecting the elongate rod to a controller adapted to generate current and supplying a current at a first amperage from the controller to the distal end of the elongate rod. Applying the current for a predetermined time so as to disrupt a biofilm on or proximate to an interior wall of the bladder.

To provide a versatile technique in accurately and quickly understanding Hunner lesion of a patient without relying on a doctor's knowledge and experience level, and to provide a technique which is obviously advanced in an accurate diagnosis of interstitial cystitis, a remedy for a patient suffering from the interstitial cystitis, and an international agreement.SOLUTION: A program causes a computer to execute a process of outputting a presence / absence of Hunner lesion or if the patient has Hunner-type interstitial cystitis or not, by inputting a target bladder endoscope image in a learning model which acquires an endoscope image data of Hunner lesion in a bladder as training data, inputs bladder endoscope image, and outputs presence / absence of Hunner lesion in the endoscope image.SELECTED DRAWING: None

The present invention discloses a forsythiaside phospholipid complex and its preparation method and application, which belong to the field of medical technology. The forsythiaside phospholipid complex includes forsythiaside and phospholipid, and its preparation method includes dissolving a certain proportion of forsythiaside and phospholipid in an organic solvent and stirring the reaction in a constant temperature water bath, and then subjecting the reaction solution to reduced pressure rotary evaporation and vacuum drying to obtain the forsythiaside phospholipid complex. The forsythiaside phospholipid complex prepared by the present invention can be prepared as an oral preparation on the one hand to improve oral bioavailability and drug distribution in lung tissue, and on the other hand, it can be prepared into a suspension by hydration, and the drug can be delivered to the lungs by intravesical instillation to treat interstitial cystitis, or delivered to the lungs by atomized inhalation to prolong the lung residence time and lung drug exposure. Compared with conventional original drug preparations, the forsythiaside phospholipid complex of the present invention significantly improves the efficacy of treating interstitial cystitis and the anti-inflammatory effect of inflammation caused by lung infection viruses and bacteria.

The application discloses application of metformin in preparation of a medicine for treating interstitial cystitis, and finds that metformin can reduce pain sensitivity of an interstitial cystitis (IC) rat, reduce edema degree of a bladder of the IC rat, restore bladder capacity of the IC rat, repair the bladder mucosa of the IC rat and reduce submucosal hemorrhage, reduce mast cell infiltration, and has a significant curative effect on interstitial cystitis, and can provide a new medicine for treating interstitial cystitis.

Provided is a drug for the treatment of Hunner-type interstitial cystitis, which can selectively inhibit I FN-gamma, has no risk of biological contamination, and can be stored at room temperature. Provided is a drug for the treatment of Hunner-type interstitial cystitis or a reagent for experimental research, which contains, as an active ingredient, a DNA oligonucleotide that has a base sequence depicted in any one of SEQ ID NO: 1 to SEQ ID NO: 3 and that selectively binds to I FN-[gamma]. In the DNA oligonucleotide containing the base sequence represented by SEQ ID NO: 3, the base X in the sequence is an artificially produced base, and the artificially produced base can be chemically modified by a low-molecular compound, a middle-molecular compound, a high-molecular compound, a biopolymer or a biocompatible polymer.

The invention provides a compound of formula (I): or a salt thereof, wherein R1-R7 and X have any of the values described in the specification, as well as compositions comprising a compound of formula (I) or a salt thereof. The compounds and salts are useful for activating a focal adhesion kinase (FAK) and for treating epithelial disease or damage. The invention also provides methods to treat bladder disease and damage, interstitial cystitis and transplant corneas with compounds discussed in herein.

Described herein are methods and kits for—inter alia—identifying a companion animal having an increased risk of developing interstitial cystitis; along with compositions for treating same.

The invention discloses an application of metformin in preparation of a medicine for treating interstitial cystitis, and finds that the metformin can reduce the pain sensitivity of an interstitial cystitis (IC) rat, reduce the bladder edema degree of the IC rat, recover the bladder capacity of the IC rat, repair the bladder mucosa of the IC rat and reduce submucosal bleeding. Macrocyte infiltration is reduced, that is, the metformin has a remarkable curative effect on interstitial cystitis, and a new medicine can be provided for treating interstitial cystitis.

To provide methods and kits for identifying a companion animal having an increased risk of developing interstitial cystitis; along with compositions for treating the same.SOLUTION: A pet food composition comprises an effective amount of a fiber-bound polyphenol component, for use in increasing the level of a urinary cytokine selected from: Fms-like tyrosine kinase 3 (F1t3-L), a stem cell factor (SCF); and IL-12p40, in a companion animal.SELECTED DRAWING: Figure 1A

The invention relates to the use of epidermal growth factor for the manufacture of a medicament for the treatment of interstitial cystitis. The "epidermal growth factor" (EGF) of the invention can be used to manufacture an excellent medicament for interstitial cystitis. The medicament has a composition that includes an active ingredient, adjuvant, dispersant, wetting agent, and / or suspension agent. The carrier of the epidermal growth factor is water, colloid, hyaluronic acid, natural oils, and / or glucose. The medicament serves to reduce urinary frequency. The medicament serves to restore bladder elasticity. The medicament serves to reduce cystitis. The medicament serves to increase the antioxidant capacity in bladder tissue.The present invention proposes a novel effect of epidermal growth factor, which can be used to treat interstitial cystitis and to repair the bladder mucosa and exhibits excellent efficacy.

The invention belongs to the field of medical device technology and relates to a formulation developed for the treatment of Interstitial Cystitis disorder in particular.

The invention provides a method of treating interstitial cystitis that applies therapeutic exomes to the bladder of a patient through intravesical administration. Unlike the intravesical administration of stem cells, the intravesical administration of exosomes permits a therapeutic amount of paracrine-active growth factors and cytokines to be applied to bladder tissue before they can voided by urination.

The invention provides systems and methods for providing a diagnostic examination to a patient, including, but not limited to a determination of the permeability of a patients' body cavity.

The invention discloses a bladder drainage medicine perfusion device, which belongs to the technical field of medical instruments and comprises a catheter, one end of the catheter is communicated with a urine storage bag, the other end of the catheter is communicated with the inside of the bladder through a first connecting tube, and two sides of the catheter are symmetrically communicated with medicine perfusion mechanisms. The medicine filling mechanism comprises a first connector communicated with the flow guide pipe, a one-way valve is arranged in the first connector, and the first connector is communicated with a medicine filling part. The catheter is connected with the urine storage bag and the bladder, and a drainage channel is established through the first connecting tube. Symmetrically-arranged medicine filling mechanisms are communicated with the flow guide pipe through first connectors, the one-way valves ensure that medicine flows into the bladder in a one-way mode, and backflow of urine is avoided. Continuous drug perfusion and drainage can be performed synchronously, limitation of traditional one-time perfusion is broken through, the contact time of the drug and the bladder mucosa is prolonged, and the curative effect is improved; due to the symmetrical design, bilateral drug delivery can be achieved, the drug distribution uniformity is enhanced, and the drug delivery device is suitable for tumor postoperative chemotherapy or interstitial cystitis treatment.

The invention belongs to the technical field of exosome application, and discloses application of a sarcodon aspratus exosome in preparation of a medicine for treating interstitial cystitis. The prepared sarcodon aspratus exosome is perfused into the bladder of a rat with interstitial cystitis, and it is found that the sarcodon aspratus exosome can significantly improve urination disorder of the model rat and relieve symptoms of interstitial cystitis. In addition, the invention also finds that (1) the sarcodon aspratus exosome can obviously reduce the expression of IL-1beta, IL-6, MCP-1, CXCL-1, ICAM-1 and BAX in the bladder tissue; (2) the sarcodon aspratus exosome can significantly reduce the activation number of mast cells and inhibit degranulation of the mast cells; and (3) the sarcodon aspratus exosome can significantly improve epithelial cell apoptosis. The research shows that the sarcodon aspratus exosome can be used for treating interstitial cystitis. The research provides a new idea for the treatment of interstitial cystitis.

The invention discloses interstitial cystitis serum polypeptide marker human serum albumin and application thereof, and belongs to the technical field of medical detection. The polypeptide is a fragment of human albumin (Albumin, ALB), the amino acid sequence of the polypeptide is as shown in SEQ.ID.NO.1, and the accurate molecular weight of the polypeptide is 1467.8 Daltons. The detection value range of the compound in the serum of normal people is 0.2499-4.8150 mg / mL, the detection value range of the compound in the serum of interstitial cystitis patients is 5.2170-9.7240 mg / mL, the compound in the serum of the patients is remarkably highly expressed, and the inter-group difference is extremely remarkable (plt; aLB can be used as a basis for preparation of interstitial cystitis diagnosis medicines and a serum diagnosis medicine target, and a new direction is provided for development of diagnosis means; the interstitial cystitis serum diagnostic drug contains a reagent capable of specifically detecting ALB, and can quantitatively or qualitatively detect ALB. The polypeptide can also be used as a target molecule for ELISA (enzyme-linked immuno sorbent assay) detection, and is beneficial to timely and accurate diagnosis of interstitial cystitis.

The invention belongs to the technical field of exosome application, and discloses a triptolide-loaded nano co-delivery drug delivery carrier and application thereof in preparation of drugs for treating interstitial cystitis. The triptolide-loaded nano co-delivery drug delivery carrier is used for interstitial cystitis model animals, and the following changes are observed: 1, the sensitivity of the model animals to stimulation is reduced; 2, the urination frequency of model animals is reduced, and the urination volume of words is increased; 3, the number of red blood cells in urine of the model animal is reduced; 4, bladder tissue hyperemia is relieved, and the size is reduced; and 5, the expression of inflammatory factors IL-6, MCP-1, ICAM-1 and BAX is obviously reduced. Therefore, it can be determined that the triptolide-loaded nano-co-delivery drug delivery carrier is used for treating interstitial cystitis. According to the research, the application range of the triptolide is expanded, and the triptolide is combined with the exosome to be used for treating the interstitial cystitis, so that a new thought is provided for treating the interstitial cystitis.

The invention discloses nano-silver polyphenol-recombinant humanized collagen bionic gel for interstitial cystitis, belongs to the field of biomedical materials and regenerative medicine, and particularly relates to a novel biomedical composite gel material. Especially aiming at the pathological characteristics of interstitial cystitis IC, silver nanoparticles, a surface polyphenol network and PDA-amine functionalized combination III type recombinant humanized collagen and a sodium alginate matrix are crosslinked through EDC / NHS or Genipin to construct a stable sustained-release system; the prepared gel shows excellent antibacterial activity, cytocompatibility, appropriate rheological properties and swelling rate in vitro, is controllable in degradation half-life period, can significantly improve frequent urination, reduce inflammation score and recover bladder capacity in an animal model, and is suitable for cystitis local perfusion treatment.

The invention relates to a urine bacterium transplantation liquid for treating interstitial cystitis, which comprises the following components: urine bacterium precipitate obtained by centrifuging urine of a healthy donor and sterile normal saline, and the concentration of the urine bacterium precipitate in the urine bacterium transplantation liquid is 0.01-0.05 g / L. The abundance of any strain of lactobacillus, corynebacterium, prevotella, staphylococcus and streptococcus in the urine bacterium transplantation liquid is located at the first ten ranks of the abundance of all strains.